Novo Nordisk rebrands as ‘Novo’ amid downgrade and pipeline setbacks

Morgan Stanley ↗ 0.81% downgraded Novo Nordisk ↘ 2.14% to Underweight from Equal-weight on September 11, citing a subdued medium-term growth outlook and rising concerns over the approaching patent cliff for semaglutide, the active ingredient behind the blockbuster drugs Ozempic and Wegovy. The bank set a price target of DKK 250, implying more than 10% downside from recent levels.ad-hoc-news+2

Semaglutide is expected to account for roughly 75% of Novo Nordisk's revenue in 2026, a concentration that leaves the company exposed as patent protection lapses in Europe and the United States in the early-to-mid 2030s. The drug's patents have already expired in several markets including India, China, and Brazil, opening the door to generic competition. Morgan Stanley's modeling assumes semaglutide will still represent 59% of revenue in 2031 — the period when exclusivity losses begin to weigh most heavily.thestreet+4

Competitive Pressure From Eli Lilly

A proprietary Morgan Stanley survey of 200 U.S. primary-care physicians pointed to market-share losses for Novo Nordisk over the next 18 months, chiefly to Eli Lilly's ↘ 0.65% Zepbound, Mounjaro, and Foundayo, with the rival drug retatrutide adding further pressure from 2027. Prescription data also showed cooling growth for Novo Nordisk's oral Wegovy pill after a strong first half of 2026, with analysts noting that Eli Lilly has captured a large share of Medicare patients through its Bridge programme.ad-hoc-news

Shares fell roughly 2.5% on September 12, the first trading day after the downgrade, and declined about 7% over the following week. Year-to-date, the stock is down approximately 16%.marketscreener+1

Rebrand and Pipeline Setbacks Cloud the Picture

The downgrade landed alongside a sweeping corporate rebrand. On September 14, Novo Nordisk officially shortened its global brand to "Novo," updating its logo so the traditional bull faces right instead of left. CEO Mike Doustdar framed the shift under the tagline "Lasting Health Starts Now," with a Capital Markets Day scheduled for September 21 in London expected to lay out the company's strategy beyond the current decade.swedenherald+2

Pipeline developments have offered mixed signals. The Phase 3 STEP Young trial showed that 40.4% of children under twelve treated with weekly semaglutide plus lifestyle support moved below the obesity threshold after 68 weeks, versus none in the placebo group. But Novo Nordisk halted Phase 3 trials of the anti-inflammatory drug ziltivekimab, and the combination therapy CagriSema failed to match Eli Lilly's tirzepatide in a head-to-head study, delivering 23.0% versus 25.5% weight loss.ad-hoc-news

The underlying business remains profitable — second-quarter net profit reached DKK 21.0 billion and free cash flow hit DKK 42.5 billion — but investors now face a company whose dominant franchise carries a visible expiration date.ad-hoc-news